Literature DB >> 3166384

Surface antigenic profile and globin phenotype of two new human erythroleukemia lines: characterization and interpretations.

T Papayannopoulou1, B Nakamoto, S Kurachi, M Tweeddale, H Messner.   

Abstract

Detailed characterization of the composite phenotype of two newly established erythroleukemia lines (OCIM1, OCIM2) shows that these lines share many of their erythroid markers (ie, surface antigens and globin program) as well as several of their nonerythroid properties (myeloid/monocytic/megakaryocytic) with the two known erythroleukemia lines (K562, HEL). In addition, each displays novel and instructive features. We argue that the surface and globin phenotype of all erythroleukemia lines is nonrandom and that it may be of physiologic relevance; it could represent the most prevalent phenotype of cells transformed by leukemia in vivo, and it raises the possibility that cells with similar potentials exist transiently during normal hematopoietic differentiation before their irreversible commitment to a single lineage. As such, these cells demonstrate a greater phenotypic adaptability in vitro than do their single lineage-committed counterparts since they can differentiate toward more than one lineage.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3166384

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  17 in total

1.  Coordinate regulation of HOX genes in human hematopoietic cells.

Authors:  M C Magli; P Barba; A Celetti; G De Vita; C Cillo; E Boncinelli
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-15       Impact factor: 11.205

2.  1,25-Dihydroxyvitamin D3 and its analogues inhibit acute myelogenous leukemia progenitor proliferation by suppressing interleukin-1beta production.

Authors:  S Peleg; H Qiu; S Reddy; D Harris; Q Van; E H Estey; M Talpaz; Z Estrov
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

3.  Participation of the human p53 3'UTR in translational repression and activation following gamma-irradiation.

Authors:  L Fu; S Benchimol
Journal:  EMBO J       Date:  1997-07-01       Impact factor: 11.598

4.  Regulation of megakaryocyte phenotype in human erythroleukemia cells.

Authors:  M W Long; C H Heffner; J L Williams; C Peters; E V Prochownik
Journal:  J Clin Invest       Date:  1990-04       Impact factor: 14.808

5.  Translational regulation of human p53 gene expression.

Authors:  L Fu; M D Minden; S Benchimol
Journal:  EMBO J       Date:  1996-08-15       Impact factor: 11.598

6.  Structure-function relationships of interleukin-3. An analysis based on the function and binding characteristics of a series of interspecies chimera of gibbon and murine interleukin-3.

Authors:  K Kaushansky; S G Shoemaker; V C Broudy; N L Lin; J V Matous; E M Alderman; J D Aghajanian; P J Szklut; R E VanDyke; M K Pearce
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

7.  Regulated high level expression of a human gamma-globin gene introduced into erythroid cells by an adeno-associated virus vector.

Authors:  C E Walsh; J M Liu; X Xiao; N S Young; A W Nienhuis; R J Samulski
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-01       Impact factor: 11.205

8.  Transcriptional regulation of the rat platelet factor 4 gene: interaction between an enhancer/silencer domain and the GATA site.

Authors:  K Ravid; T Doi; D L Beeler; D J Kuter; R D Rosenberg
Journal:  Mol Cell Biol       Date:  1991-12       Impact factor: 4.272

9.  Expression of wild-type p53 is not compatible with continued growth of p53-negative tumor cells.

Authors:  P Johnson; D Gray; M Mowat; S Benchimol
Journal:  Mol Cell Biol       Date:  1991-01       Impact factor: 4.272

10.  CRISPR/Cas9 knockouts reveal genetic interaction between strain-transcendent erythrocyte determinants of Plasmodium falciparum invasion.

Authors:  Usheer Kanjee; Christof Grüring; Mudit Chaand; Kai-Min Lin; Elizabeth Egan; Jale Manzo; Patrick L Jones; Tiffany Yu; Robert Barker; Michael P Weekes; Manoj T Duraisingh
Journal:  Proc Natl Acad Sci U S A       Date:  2017-10-19       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.